Flortaucipir F-18 Patent Expiration

Flortaucipir F-18 was first introduced by Avid Radiopharmaceuticals Inc in its drug Tauvid on May 28, 2020.


Flortaucipir F-18 Patents

Given below is the list of patents protecting Flortaucipir F-18, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Tauvid US8932557 Imaging agents for detecting neurological dysfunction May 26, 2032 Avid Radiopharms Inc



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Flortaucipir F-18's patents.

Given below is the list recent legal activities going on the following patents of Flortaucipir F-18.

Activity Date Patent Number
Patent litigations
Patent Term Extension Certificate 18 Oct, 2023 US8932557
Notice of Final Determination -Eligible 01 Sep, 2023 US8932557
FDA Final Eligibility Letter 26 Apr, 2023 US8932557
transaction for FDA Determination of Regulatory Review Period 30 Jun, 2022 US8932557
Payment of Maintenance Fee, 8th Year, Large Entity 22 Jun, 2022 US8932557
Second letter to regulating agency to determine regulatory review period 05 Nov, 2021 US8932557
Letter from FDA or Dept of Agriculture re PTE application 14 Dec, 2020 US8932557
Initial letter Re: PTE Application to regulating agency 05 Nov, 2020 US8932557
Patent Term Extension Application under 35 USC 156 Filed 28 Aug, 2020 US8932557
Patent Term Extension Application under 35 USC 156 Filed 16 Jul, 2020 US8932557